Biostate AI

?? Exciting Update: Biostate AI's Wefunder Campaign Featured on KingsCrowd! We are thrilled to announce that Biostate AI's ongoing Wefunder campaign has been spotlighted in a recent article by KingsCrowd, a leading platform for startup investment insights. This feature underscores the innovative strides we're making in personalized healthcare through AI and genomics. Key Highlights from the KingsCrowd Feature: - AI-Driven Health Predictions: Our platform leverages artificial intelligence to anticipate individual health changes, aiming to predict diseases before they emerge and tailor treatments to each person's unique genetic makeup. - Extensive Clinical Collaborations: We've analyzed over 8,000 biological and clinical samples using our proprietary RNA sequencing (RNAseq) and AI technologies. Our collaborations include prestigious institutions such as Harvard Medical School, MD Anderson Cancer Center, and Cornell University. - Strong Intellectual Property Portfolio: We have a portfolio of twelve pending patents encompassing both AI and biotechnology innovations, reinforcing our commitment to pioneering advancements in healthcare. - Experienced Leadership: Our co-founders, David Zhang and Ashwin Gopinath, bring extensive expertise in biotech innovation and AI development, having previously served as professors at MIT and Rice University. Join Us in Revolutionizing Healthcare Our Wefunder campaign is currently live, offering a unique opportunity for investors to be part of the future of personalized medicine. With a minimum investment of just $100, you can join us in transforming how diseases are predicted and treated. Invest Today and Be Part of the Change Don't miss this chance to invest alongside top venture capitalists and industry experts. Your support will help accelerate our research and development efforts, bringing us closer to a world where healthcare is uniquely tailored to each individual. ?? Invest Now on Wefunder: https://lnkd.in/eiKeqf7A Thank you for being part of our journey toward a healthier future!

??Biostate AI Weekly Tech Insight Revolutionizing Alzheimer's Detection with Blood Tests A groundbreaking study in JAMA has unveiled the potential of multi-modal blood biomarkers for the early detection of Alzheimer's disease, bringing us closer to minimally invasive screening and personalized interventions. Conducted by the Atherosclerosis Risk in Communities (ARIC) study, the research analyzed over 1,500 participants' biomarkers over 20+ years, revealing early signals of Alzheimer’s, even as early as midlife. Key takeaways: - Multi-modal biomarkers (like amyloid-beta, tau, and neurofilament light) tracked over time give deep insights into Alzheimer’s risk. - The integration of biomarkers could open doors to early detection and personalized risk stratification. - These methods could even inspire early detection strategies in urological oncology, for cancers like prostate and bladder. ?? View full Breakdown: https://lnkd.in/edGD_wJa At Biostate AI, we’re using cutting-edge AI technology to drive similar breakthroughs in AI-powered diagnostics and personalized healthcare, advancing the future of precision medicine for all! ?? #BiostateAI #AlzheimersResearch #Biomarkers #PrecisionMedicine #EarlyDetection #HealthcareInnovation?#MedicalResearch

?? We’re officially LIVE on Wefunder! ?? Over the past year, we’ve been building something truly special, and we’re thrilled to invite you to be part of this journey. Biostate AI is transforming medicine with AI-driven precision healthcare, and now, you can help shape the future. After raising $8M+ from accredited and institutional investors, we’re opening the doors to our community to invest in the future of AI-powered diagnostics and personalized medicine. ?? Why Invest in Biostate AI? ? Breakthrough AI for Disease Prediction – Changing how medicine is practiced. ? 80% Cost Reduction in RNA Sequencing – Making precision medicine more accessible. ? $200B+ Market Opportunity – AI-driven solutions in biotech and drug discovery. ? Backed by Top VCs & Biotech Experts – Invest alongside Accel, Matter Venture Partners, leaders from Anthropic, 10X Genomics, and Twist Biosciences. This is more than an investment—it’s an opportunity to change healthcare forever. Join us before it’s too late! ?? Invest now before the discount disappears: https://lnkd.in/eiKeqf7A #BiostateAI #HealthTech #Innovation #AI #Wefunder #StartupInvesting

?? Exciting Milestone at Biostate AI: Bayosthiti Officially Incorporated! We’re thrilled to reflect on an incredible achievement—last month, our Indian subsidiary, Bayosthiti, was officially incorporated! This accomplishment wouldn't have been possible without the relentless effort and dedication of every single member of our team. We’ve been fortunate to establish global academic partnerships, including with renowned hospitals and academic institutions across India and around the world. To date, we’ve established partnerships with 66 hospitals and academic organizations globally and analyzed over 8,000 clinical samples. ?? As we look ahead, we are excited about the future of Bayosthiti and the opportunities that lie in our continued growth. With our new Indian subsidiary, we are poised to expand our global reach even further, advancing innovation and collaboration in the biotech space. Thank you to all our collaborators for your ongoing support. We look forward to achieving even more together! ?? #BiostateAI #Bayosthiti #GlobalExpansion #Biotech #Innovation #Teamwork #ClinicalResearch #Partnerships #Growth

?Biostate AI Weekly Tech Insight Breakthrough in Gonorrhea Treatment: Rapid RNA-based Test Detects Antibiotic Resistance in Minutes Researchers at Caltech have introduced a groundbreaking technique for the rapid detection of antibiotic resistance in Neisseria gonorrhoeae, the bacterium responsible for gonorrhea. This RNA-based method can ascertain antibiotic susceptibility in just 10 minutes, significantly outpacing traditional culture-based diagnostics. - The Need for Speed in Diagnostics With gonorrhea ranking as the second most prevalent sexually transmitted infection in the U.S., and resistance to antibiotics rising alarmingly, the ability to quickly determine the right treatment is more crucial than ever. Current diagnostic practices, which can take up to two days, often result in the use of broad-spectrum antibiotics that further drive resistance. - An Innovative RNA-Based Solution By tracking changes in RNA markers within minutes of antibiotic exposure, Caltech's team has created a phenotypic testing approach that could transform point-of-care diagnostics. Early trials using ciprofloxacin have shown that susceptible strains of N. gonorrhoeae exhibit significant changes in gene expression quickly, while resistant strains do not. - Implications for Global Health This rapid testing method holds the potential to dramatically enhance how healthcare providers treat gonorrhea worldwide, ensuring effective use of antibiotics and slowing the spread of resistance. However, further research is needed to refine the technique and adapt it for clinical use. ?? View full Breakdown: https://lnkd.in/ecwqN7qE #HealthcareInnovation #biostateAI #AntibioticResistance #MedicalResearch #PointOfCare

??Biostate AI?All Hands Meeting Recap Last week, we gathered for our All Hands Meeting, where the entire?Biostate AI?team came together to align on our goals, celebrate our achievements, and discuss exciting developments ahead. From highlighting the groundbreaking progress in our projects to brainstorming new ways to tackle challenges, it was a fantastic opportunity to strengthen our collaboration and share insights across teams.??? We’re incredibly proud of the energy, passion, and dedication each member brings to?Biostate AI. And to show our appreciation, each team member received a little gift as a thank-you for all their hard work! On Valentine’s Day, we also want to take a moment to express our gratitude to our amazing collaborators and partners. Your continued support and collaboration help fuel our success.??? #BiostateAI #Teamwork #Innovation #Biotech #CompanyCulture

What makes Biostate AI’s team unique? Our Operations Manager Kristina shares what drives our team culture: ? Honesty, enthusiasm, and intelligence ? A shared passion for solving challenges together ? A team that steps up when it matters most ?? At Biostate AI, it’s not just about skills—it’s about mindset! ?? Watch the full interview now! https://lnkd.in/g9MHFnyu #BiostateAI #HealthTech #Innovation

Join Our Referrer Program and Get 20% Off Your Next Order! We’re excited to introduce our Referrer Program, where you can earn rewards by referring new customers to Biostate.AI. When you refer a collaborator to us, you’ll receive 20% off your next order once their project is confirmed. If you know someone who could benefit from our comprehensive, affordable, and fast Total RNASeq services, send them our way—we’d love to hear from you! Learn more at?www.biostate.ai?or contact us at?[email protected]

???????? ???? ????????????????, ?????? ?????? ???????? ???????????????? ???? ????????? Our CEO Dave Zhang explains: A "Biostate" is your body’s molecular snapshot — RNA, DNA, proteins, and metabolites. Biostate AI predicts your health outcomes, just like ChatGPT predicts words, helping us understand your body under different conditions. ??????????????????????????????? ???????????? ???????? ???? ?????? ??????????-??????????. ? Watch the full interview now! https://lnkd.in/gZgqyRNK #BiostateAI #HealthTech #Innovation

???????? ???? ????????????????, ?????? ?????? ???????? ???????????????? ???? ????????? Our CEO Dave Zhang explains: A "Biostate" is your body’s molecular snapshot — RNA, DNA, proteins, and metabolites. Biostate AI predicts your health outcomes, just like ChatGPT predicts words, helping us understand your body under different conditions. ??????????????????????????????? ???????????? ???????? ???? ?????? ??????????-??????????. ? Watch the full interview now! https://lnkd.in/gZgqyRNK #BiostateAI #HealthTech #Innovation